Combinostics, a neurology technology company looking at everything from early detection and diagnosis to the ongoing management of neurological disorders, has announced the Dementia Differential Analysis report, which aims to assist clinicians in the detection and differential diagnosis of dementias. The report will be available in an upcoming software release. Existing technologies compare against cognitively normal reference data only – the artificial intelligence-enabled application quantifies and evaluates patient MRI data against the distributions of key dementia-specific imaging biomarkers and reference data from approximately 2,000 patients with a confirmed neurodegenerative disease, including frontotemporal dementia, Alzheimer's disease and vascular dementia, the company explained. "The Dementia Differential Analysis report will help change the paradigm of diagnosing dementias," contended Richard Hausmann, CEO of Combinostics. Using the company's AI technology, it enables differential diagnostic support, furthering the company's commitment to provide clinicians with tools for reliable, evidence-based diagnostic decisions, he added.

New Finnish technology is tapping into machine learning and artificial intelligence to support healthcare professionals in early diagnosis of neurological disorders. When a person is suspected of having a memory disorder, they undergo extensive tests ranging from brain scans to neurological examinations. It is then up to their physician to analyse the results. However, even an experienced doctor may struggle to arrive at an accurate diagnosis during the early stages of a disease. Finnish healthtech company Combinostics has a solution for this in mind: its cloud-based tools for the comprehensive analysis of patient data.